# VolitionRX Limited

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/VolitionRX Limited).

## Overview

VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease. Its portfolio includes the Nu.Q® family of tests and services for human and animal health, with commercialization through direct sales, distributors, and licensing partners across multiple countries.

## Products & services

• Nu.Q® Vet Cancer Test for companion animals
• Nu.Q® Canine Cancer Test through IDEXX
• Nu.Q® Discover assay and service offerings
• Nu.Q® H3.1 NETs assay components for partner development
• Licensing and supply agreements for diagnostic commercialization

- **Veterinary cancer diagnostics** (55%) — Blood-based tests for detecting and monitoring cancer in companion animals.
- **Human disease diagnostics** (25%) — Assay technologies and services aimed at human diagnostic applications and partner development.
- **Nu.Q® Discover services** (15%) — Research and assay services sold to partners and customers for biomarker discovery and validation.
- **Licensing and collaboration agreements** (5%) — Technology access, supply, and commercialization rights granted to diagnostic partners.

- Nu.Q® Vet Cancer Test for companion animals
- Nu.Q® Canine Cancer Test through IDEXX
- Nu.Q® Discover assay and service offerings
- Nu.Q® H3.1 NETs assay components for partner development
- Licensing and supply agreements for diagnostic commercialization

## Customers

VolitionRx sells to diagnostic companies, reference laboratories, veterinary networks, and research partners that want biomarker-based tests they can commercialize or run in their own platforms. In animal health, customers include veterinary laboratories and distributors serving companion-animal clinics, while in human health the company works with specialized diagnostics groups developing assays for disease areas such as thrombosis and cancer. The business model depends on partners with established distribution, laboratory infrastructure, and regulatory/commercial reach.

- **Veterinary reference laboratories** (primary) — Buy Nu.Q® Vet Cancer Test products to run cancer screening and monitoring workflows for companion animals.
- **Diagnostic partners and licensors** (primary) — License Volition's assay technology and supply agreements to commercialize tests on their platforms.
- **Veterinary distributors** (secondary) — Purchase and distribute Nu.Q® Vet Cancer Test into regional animal-health markets.
- **Research and clinical collaborators** (secondary) — Use Nu.Q® Discover and assay components to evaluate biomarker performance and clinical utility.
- **Human diagnostics developers** (emerging) — Evaluate Nu.Q® components for indications such as APS and other NETs-related diseases.

- Veterinary reference laboratories buying tests for companion-animal screening
- Diagnostic partners licensing assays for their own platforms
- Distributors selling tests into veterinary clinic networks
- Research and clinical collaborators validating biomarker utility
- Human diagnostics companies exploring NETs-related indications

## Geography

VolitionRx operates as a multinational diagnostics business with commercialization and partner activity spanning the United States, Europe, and Asia. Its Nu.Q® Vet Cancer Test is available in over twenty countries, and the company relies on regional distributors and global partners such as IDEXX, Fujifilm Vet Systems, Werfen, and Hologic to extend market access. Geography matters because regulatory pathways, veterinary practice adoption, and partner networks differ by country and determine how quickly tests can be launched and scaled.

- United States is the corporate base and a key commercialization market
- UK and Ireland were early launch markets for Nu.Q® Vet Cancer Test
- Japan is a commercial market through Fujifilm Vet Systems
- Over twenty countries now have access to Nu.Q® Vet Cancer Test
- Global partners provide reach into reference labs and specialized diagnostics

## Strategy

VolitionRx's strategy is to monetize its biomarker IP through licensing, supply, and distribution partnerships rather than building a fully direct sales organization everywhere. The company is focused on expanding the Nu.Q® platform in companion animal health while also developing human diagnostic applications with established diagnostics companies that can provide regulatory, laboratory, and commercial infrastructure.

- **Commercialize Nu.Q® through strategic partners** (short-term) — Partners provide distribution, laboratory capacity, and market access that Volition lacks at scale.
- **Expand veterinary diagnostics footprint** (medium-term) — Companion-animal testing is the most visible commercialization path for the Nu.Q® platform.
- **Build human diagnostic applications** (medium-term) — Human disease indications could broaden the addressable market and deepen IP monetization.

- Partner with established diagnostics companies for commercialization
- Expand Nu.Q® Vet Cancer Test availability across more countries
- Monetize IP through licensing and product supply agreements
- Develop human NETs-related and cancer applications with partners
- Use reference-lab and point-of-care channels to broaden access

## Risks

VolitionRx depends on external financing and partner execution, so commercialization risk is tied to both capital availability and third-party adoption. Its products are subject to regulatory, clinical validation, and reimbursement hurdles, while the company also faces typical diagnostics risks such as slow market uptake, competitive assay technologies, and dependence on a small number of strategic partners.

- **Dependence on external financing** [high] — The company has not achieved sustained profitability and needs capital to fund operations and commercialization.
- **Partner concentration** [high] — Commercial reach relies heavily on a limited number of licensing and distribution partners.
- **Regulatory and clinical validation** [high] — Diagnostic products must demonstrate utility and may require approvals or evidence generation before broad adoption.
- **Commercial adoption risk** [medium] — New blood-based tests can take time to gain routine use in veterinary and human workflows.
- **Competitive technology risk** [medium] — Other diagnostics companies may offer alternative biomarker or liquid biopsy solutions.

- Going-concern and financing dependence
- Partner concentration and execution risk
- Regulatory and clinical validation risk
- Slow adoption of new diagnostic tests
- Competition from other biomarker and liquid biopsy platforms

## Accounting

Key accounting judgments include deferred revenue, warrant and derivative liability valuation, stock-based compensation, and impairment testing for intangible assets. Because the company uses licensing and supply arrangements, revenue timing can depend on contract terms, milestone recognition, and service delivery, while financing instruments can create fair-value volatility in reported results.

- **Deferred revenue and contract accounting** — Affects timing of reported revenue and contract liabilities
- **Warrants and derivative liabilities** — Can create non-cash gains or losses in other income/expense
- **Intangible asset impairment** — Could lead to impairment charges if expected use declines
- **Stock-based compensation** — Impacts reported R&D, sales, and G&A costs

- Deferred revenue and milestone recognition under partner contracts
- Fair value accounting for warrants and derivative liabilities
- Stock-based compensation valuation
- Impairment testing for intangible assets and IP
- Lease accounting and borrowing-rate assumptions

---

*Last updated: 2026-04-29T05:07:11.658850+00:00*